Month: March 2015

HIV Activist Raises Hope and Warnings in New Attachment Inhibitor Trial.

Video: HIV Activist Raises Hope and Warnings in New Attachment Inhibitor Trial. Leading HIV activist Nelson Vergel raises hopes but also warns HIV salvage patients and their physicians about functional monotherapy risks in the Bristol-Meyers Squibb (BMS) new attachment inhibitor study (Fostemsavir, BMS-663068) currently enrolling (2015-2016). This innovative drug, along with Taimed’s ibalizumab, can be the …

HIV Activist Raises Hope and Warnings in New Attachment Inhibitor Trial. Read More »

Starting HIV Medications Within First Weeks of Infection Decreases Hidden Virus

Clin Infect Dis. (2015) doi: 10.1093/cid/civ171First published online: March 3, 2015 Impact of the Earliness of Antiretroviral Therapy Initiation During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA Moussa Laanani1,2, 1Inserm, CESP Centre for Research in Epidemiology and Population Health, U1018, Paris-Sud University, Le Kremlin-Bicêtre, France 2APHP, Department of Epidemiology and Public Health, Bicêtre Hospital, Le Kremlin-Bicêtre, France …

Starting HIV Medications Within First Weeks of Infection Decreases Hidden Virus Read More »

Most Important HIV Research Reports from CROI 2015

From Jules Levin: perhaps the biggest stories out of CROI from my perspective are the development of 2 new HIV therapies – the new attachment inhibitor & the new maturation inhibitors, as well as the safety & efficacy of TAF, and an important message out of CROI is that TAF can also be used in HCV coinfected patients as a replacement …

Most Important HIV Research Reports from CROI 2015 Read More »

Scroll to Top